Shedding light on the performance of a pyrosequencing assay for drug-resistant tuberculosis diagnosis.

ABSTRACT:

Background

Rapid molecular diagnostics, with their ability to quickly identify genetic mutations associated with drug resistance in Mycobacterium tuberculosis clinical specimens, have great potential as tools to control multi- and extensively drug-resistant tuberculosis (M/XDR-TB). The Qiagen PyroMark Q96 ID system is a commercially available pyrosequencing (PSQ) platform that has been validated for rapid M/XDR-TB diagnosis. However, the details of the assay's diagnostic and technical performance have yet to be thoroughly investigated in diverse clinical environments.

Methods

This study evaluates the diagnostic performance of the PSQ assay for 1128 clinical specimens from patients from three areas of high TB burden. We report on the diagnostic performance of the PSQ assay be

SUBMITTER: Georghiou SB 

PROVIDER: S-EPMC5006534 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature